Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on EBOS Group Limited (AU:EBO – Research Report), Craneware (GB:CRW – Research Report) and GlaxoSmithKline (GB:GSK – Research Report).
EBOS Group Limited (AU:EBO)
In a report issued on February 22, Adrian Allbon from Jarden maintained a Hold rating on EBOS Group Limited. The company’s shares closed last Tuesday at A$34.48.
Allbon has an average return of
According to TipRanks.com, Allbon is ranked #7376 out of 8764 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for EBOS Group Limited with an A$34.80 average price target.
See the top stocks recommended by analysts >>
Craneware (GB:CRW)
Berenberg Bank analyst Sean Thapar reiterated a Buy rating on Craneware yesterday and set a price target of p2600.00. The company’s shares closed yesterday at p2080.00.
According to TipRanks.com, Thapar is ranked #7552 out of 8764 analysts.
Craneware has an analyst consensus of Moderate Buy, with a price target consensus of p2600.00.
GlaxoSmithKline (GB:GSK)
In a report released yesterday, Seamus Fernandez from Guggenheim upgraded GlaxoSmithKline to Buy, with a price target of £20.31. The company’s shares closed last Tuesday at p1675.90, close to its 52-week low of p1519.79.
According to TipRanks.com, Fernandez is a 5-star analyst with an average return of
Currently, the analyst consensus on GlaxoSmithKline is a Moderate Buy with an average price target of p1767.90, a 5.3% upside from current levels. In a report issued on February 20, Deutsche Bank also maintained a Buy rating on the stock with a £19.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AU:EBO:
